EGFR and non-small cell lung carcinoma: The NEJ002 study [111] was prematurely closed after accruing 230 patients due to a significant benefit seen for gefitinib versus carboplatinum/paclitaxel in patients with prospectively identified EGFR-mutated advanced non-small cell lung cancer.